Advancing Engineered Phages Toward Clinical Reality

• Presenting ongoing phase 1b/2a study and clinical development plan for SNIPR001, a cocktail of engineered, CRISPR-armed phages targeting E. coli
• Discussing other uses of SNIPR001 based on in vivo preclinical data and a case study
• Outlining the critical steps toward building a regulatory and clinical evidence base that can support the first approvals of engineered phage products

Speakers:

Jonas Hink

Chief Medical Officer

SNIPR Biome